Female, n (%) |
39 (90.7) |
57(77.9) |
0.126 |
Age |
59.4±14.5 |
53.8±14.5 |
0.037 |
Smoking history, n (%) |
6 (14) |
15 (20.8) |
0.629 |
CTD disease duration (median) |
6 (1-16) |
6 (1-12) |
0.719 |
Concomitant steroid usage** |
17 (39.5) |
26 (36) |
0.722 |
CTD subtype n (%)
SSc
RA
pSS
IMS
IPAF
Other
|
5(10.6)
8 (50)
7(43.8)
9 (65)
13 (65)
1 (50)
|
42(89.4)
8(50)
9 (56.3)
5(35)
7 (35)
1 (50)
|
<0.001
|
csDMARD usage n (%)
bDMARD usage n (%)
|
25(58 )
1 (2)
|
45 (62.5)
2 (2.5)
|
0.771
0.902
|
ILD pattern on HRCT, n (%)
NSIP n (%)
SSc
RA
pSS
IMS
IPAF
UIP n (%)
SSc
RA
pSS
IMS
IPAF
|
30(69.8)
4 (9.5)
3 (50)
5 (45.5)
8 (61)
10 (66.7)
12(27.9)
1 (20)
5 (50)
2 (40 )
1 (100)
3 (60)
|
57 (79)
38 (90.5)
3 (50)
6 (54.5)
5 (38.5)
5 (33.3)
14(19.4)
4 (80)
5 (50)
3 (60)
-
2 (40)
|
0.563
[2]0.552
|
Percentage of lung reticulation on HRCT, median (IQR) |
30 (5-55 ) |
30
(10-20) |
0.901 |
Extent of Lung Involvement (limited group %) |
16(37.2%) |
15(20.8%) |
0.081 |
MMRC*, (median) |
2 (0-4) |
2 (1-3) |
0.427 |
DLCO (%)*(median) |
58 (41-75) |
59 (40-78) |
0.630 |
FVC, liter* |
2.33(1.37- 3.29) |
2.19 (1.13-3.25 ) |
0.689 |
FVC, predicted % (median) |
83 (55-111) |
72 (61-83) |
0.032 |
GAP score |
1 (0-2) |
1 (0-2) |
0.33 |